Advanced searches left 3/3

Metastatic melanoma braf - Crossref

Summarized by Plex Scholar
Last Updated: 22 April 2022

* If you want to update the article please login/register

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study

Although TT allows for rapid disease control, secondary TT resistance increases the duration of responses, although TT allows for rapid disease detection. CPI reactions have a slower start but can be long-lived in a subset of patients. According to the first and second-line therapies, respectively, 135 patients with BRAF-mutated, metastatic melanoma who received continuous therapy with TT followed by CPI, or vice versa. Patients receiving front-line CPI containing front-line CPI tended to significantly higher response rates to second-line drugs. In patients treated with front-line CPI, rapid disease progression was less common, and subsequent treatment with TT resulted in improved survival rates, according to our findings. In a subgroup of previously untreated BRAF-mutant metastatic melanoma patients, sequential therapy with front-line CPI is shown to improved tumor control and overall survival.

Source link: https://doi.org/10.3390/cancers14092082


Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis

Based on the pooled risk ratios and 95% confidence intervals, we gathered evidence on the cumulative incidence of any-grade AEs, which includes grades 1-5 AEs and severe AEs. The acceptability of combined dabrafenib and trametinib is superior to the combination of vemurafenib and cobimetinib in any-grade AEs. Moreover, nivolumab along with ipilimumab increases any-grade AEs more often than single-agent ipilimumab or nivolumab. In combination with binimetinib and a mixture of vemurafenib and cobimetinib, the results are superior to encorafenib and cobimetinib. Conclusions BRAF V600-mutant melanoma patients have the lowest AE risk treatment options. Moreover, single-agent dabrafenib can be used as the first choice in monotherapy, and the combination of dabrafenib and trametinib is the most commonly used combination therapy. Overall, the combination of immunotherapy medications raises any-grade and severe AEs more than a single agent, although the condition of targeted therapy products cannot be simply generalized.

Source link: https://doi.org/10.3389/fonc.2022.865656


Transcriptional landscape in BRAF wild type metastatic melanoma

Abstract Melanoma is a relatively uncommon disease worldwide, but it has a major role in several countries, including Europe. We compared the gene expression of six independent tumours to the expression profile of healthy melanocytes in order to shed some light on the transcriptional profile of skin melanoma. Overall, 50 up- and 19 down-regulated transcripts were found to be significantly different in tumors when compared to control tissue. Interestingly, Gene Set Enrichment Analysis, as well as the analysis of the expression results obtained from TCGA/GTEx databases, confirmed the general trend of downregulation affecting cytoribosome proteins.

Source link: https://doi.org/10.1101/2022.03.31.486532


Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism

Abstract Purpose: The BRAFV600MUT metastatic melanoma, cyclin D–CDK4/6–INK4–Rb pathway modifications are involved in resistance to MAPK inhibitors, causing BRAFV600MUT's resistance to MAPK inhibitors, resulting in a medical benefit of cyclin-dependent kinase 4 inhibitors, indicating a clinical benefit of cyclin-dependent kinase 4 inhibitors Patients and Methods: Patients with BRAFV600E/KMUT metastatic melanoma harbouring CDKN2A deficion and RB1 expression were included and stratified into two groups based on recent BRAF inhibitor therapy. In strata 1, two patients developed DLT, which characterized the MTD at palbociclib 25 mg and vemurafenib 960 mg in strata 2. The role of CHEK2 in the response to palbociclib was demonstrated by the baseline differential mRNA expression analysis and in vitro results. Conclusions: Although palbociclib and fixed-dose vemurafenib did not result in an elevated palbociclib dose above 25 mg, a significant medical benefit was achieved in pretreated patients with melanoma. An association was drawn between transcriptomic results and clinical response.

Source link: https://doi.org/10.1158/1078-0432.ccr-20-4050


Abstract 422: Sequential targeted therapy and immunotherapy of a BRAF positive metastatic melanoma patient with BRAF inhibitor vemurafenib, MEK inhibitor cobimetnib and a novel PD-1 antibody Sintilimab

Abstract BRAF mutated melanoma patients have dramatically improved the outcome of BRAF mutated melanoma patients. An oncologist must investigate multiple clinical variables before making a decision on targeted therapy alone, immunotherapy alone, targeted therapy/immunotherapy combo, or immunotherapy after targeted therapy. Because of practical reasons, we here chronicle the escalating treatment of a BRAF positive metastatic melanoma patient with non-standard regimes. The patient's response was confirmed by the significant reduction and softening of the left axillary node, as vemurafenib was China's only approved melanoma targeted therapy drug at the time of diagnosis. When the patient presented a pattern of lymph node metastases, the BRAF/MEK inhibitor combination was selected as the second-line therapy from December 2019. PD-L1 expression was discovered in 4% of tumor cells, and immunotherapy was chosen as the third-line therapy as the third-line treatment. Given the high cost of immunotherapy and the fact that Sintilimab is China's only PD-1 inhibitor on the National Reimbursement Drug List, the patient began using Sintilimab off-label and obtained partial response. His case demonstrated that effective clinical responses could be obtained with sequential targeted therapy/immunotherapy in BRAF-mutated metastatic melanoma, as well as the novel PD-1 antibody Sintilimab for metastatic melanoma. BRAF inhibitor vemurafenib, MEK inhibitor cobimetnib, and a new PD-1 antibody Sintilimab [abstract].

Source link: https://doi.org/10.1158/1538-7445.am2021-422


Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes

In 90 melanoma samples, we compared the Idylla BRAF Mutation Test and the anti-BRAF V600E immunohistochemistry, with a focus on a small cohort of 32 positive sentinel lymph nodes. The incidence of the BRAFV600E mutation in both BRAF Idylla and BRAF IHC was 33%. With the IdyllaTMBRAF Mutation Test, we found that although the agreement rate was high, we propose that IHC is more suitable for rapid BRAF testing on sentinel lymph node biopsies when associated with a low percentage and scattered tumor cells, raising the possibility of non-contributory analysis and/or false negative findings.

Source link: https://doi.org/10.3390/diagnostics12030751


STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma

With separate mechanisms of action and different response styles, the combination of targeted agents and immunotherapy to treat patients with BRAF V600-mutant melanoma may help patients. In treatment-nay patients with metastatic or unresectable locally advanced BRAF V600-mutant melanoma in comparison to pemozumab, a random, double-blind trial aims to determine the efficacy and safety of encorafenib, binimetinib, and penetolizumab.

Source link: https://doi.org/10.2217/fon-2021-1486


The FBXO4 Tumor Suppressor Functions as a Barrier to Braf V600E -Dependent Metastatic Melanoma

P16 INK4A, an allosteric inhibitor of CDK4/6, has been inactivated in over half of human melanomas, according to clinical research, and several animal models have shown that p16 INK4A deletion causes melanoma. We report that Fbxo4 deficiency causes Braf-driven melanoma and that this phenotype is linked to mouse cyclin D1 accumulation, underscoring the importance of this ubiquitin ligase in tumor suppression. FBXO4 I377M, a substrate-binding mutation that selectively disrupts cyclin D1 degradation while preserving proteolysis of the other well-known FBXO4 substrate, TRF1.

Source link: https://doi.org/10.1128/mcb.00706-13


Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma

Methods: Patients with newly diagnosed BRAF-mutated metastatic melanoma were collected from the Canadian Melanoma Research Network, and retrieved from the Canadian Melanoma Research Network, providing national prospective data. In the 1L-IO group, there were more patients with ECOG 0–1 than in the 1L-TT group compared to the 1L-TT group. However, 1L-TT after 2L-therapie, 1L-IO, 2L-TT, and 1L-TT without 2L therapy had the longest OS compared to 1L-IO without 2L therapy, 1L-IO, 2L-TT, and 1L-TT without 2L therapy. OS improvement in patients receiving 2L-total therapy and those who received 2L-IO showed a trend toward OS improvement in comparison to the 2L-TT group.

Source link: https://doi.org/10.3390/curroncol29030126

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions